Rigetti Computing
Superconducting in a Trapped-Ion Library

Executive Summary

Rigetti is the public-market superconducting quantum-computing pure-play, the same modality IBM, Google and Amazon are building, but at 1/100th their R&D budget. The thesis is binary in a way IONQ's is not: either Rigetti carves out a credible architectural niche (custom tunable-coupler chip designs; modular multi-chip systems) and rides the NISQ-to-fault-tolerant transition, or it gets squeezed out as the incumbents commercialize. FY2024 revenue was just $10.8M², roughly one-tenth of IonQ's, and the trailing EV/Sales multiple sits north of 340×. The 84-qubit Ankaa-3 launched on Rigetti QCS in December 2024 and rolled out on AWS Braket and Microsoft Azure Quantum in early 2025; the 100-qubit Ankaa-4 targets late-2026; a 336-qubit Lyra modular system is the late-2026 milestone, with a 1,000+ qubit system targeted for 2027. Our base-case discounted EV/Sales model implies ~$11 vs the $14 close, a clean-execution bull case supports ~$22, a bear case ~$4.

The Four Pillars of the Debate

Investment Thesis

The RGTI debate is binary on architecture and asymmetric on dilution. Rigetti has to either close the fidelity gap to trapped-ion and outflank the deep-pocketed superconducting incumbents (IBM Heron, Google Willow), or it gets squeezed into a research-vendor role. We frame three scenarios using a discounted EV/Sales model, RGTI is pre-profit, so a DCF is inappropriate.

Targets are the output of a simplified discounted EV/Sales model with subjective assumptions, illustrative, not analyst price targets. See sections 08 and 10 to adjust. Probability weights are symmetric 25/50/25 to reflect the high outcome dispersion characteristic of pre-profit deep-tech with both architectural and capital-structure tails.

Business Overview

Rigetti builds superconducting transmon quantum processors, the same fundamental modality as IBM, Google and Amazon's Ocelot, but with a differentiated focus on custom tunable-coupler chip designs and modular multi-chip "stitched" architectures. The thesis is that transmons win on raw gate speed (microseconds vs trapped-ion milliseconds) and on the manufacturability curve (standard semiconductor fab tooling), while custom couplers can close the fidelity gap that has historically favored trapped-ion.

The product line is the Ankaa family. Ankaa-2 (84 qubits, square lattice, ~98% median 2Q fidelity) went live in late 2023; Ankaa-3 launched on Rigetti's Quantum Cloud Services platform in December 2024 with the same 84-qubit count but materially improved fidelity (~99.5% median two-qubit) and rolled out on AWS Braket and Microsoft Azure Quantum in early 2025. Ankaa-4: targeting 100 qubits and >99.7% median two-qubit fidelity, is the 2026 commercial milestone. Beyond that, the 336-qubit Lyra modular system (four stitched 84-qubit chips) is the publicly-stated late-2026 target, with a 1,000+ qubit system targeted for 2027; together they are the first systems at scale that meaningfully validate the "modular stitching" thesis vs IBM/Google monolithic-chip approaches.

The Architecture Trade-Off: Superconducting vs Trapped-Ion

Neither modality is "right", they are architectural bets on which engineering problem (fidelity vs scaling) gets solved first. Superconducting wins the fab game; trapped-ion wins the error-rate game. Rigetti is betting that as logical-qubit construction matures, fab scaling becomes the binding constraint.

Industry & Quantum Cycle

The quantum-computing sector is in the NISQ era (Noisy Intermediate-Scale Quantum, ~2024–2026): 100–2,000 physical qubits, limited error correction, very few production workloads. The gating milestone for the next phase is fault tolerance: the point at which logical qubits constructed from physical qubits can run arbitrarily long algorithms with bounded error. Google's Willow (2024) was the first below-threshold error-correction demonstration; IBM targets fault tolerance by 2029.

Within NISQ, four modalities compete in public markets and the labs. Superconducting (Rigetti, IBM, Google, Amazon Ocelot), fast gates, fab-friendly, fidelity-limited. Trapped-ion (IonQ, Quantinuum, Oxford Ionics), highest fidelity, slowest gates, hardest to scale physically. Neutral-atom (Atom Computing, Pasqal, QuEra), strong qubit-count scaling, mid-tier fidelity, room-temperature, optical traps. Photonic (PsiQuantum, Xanadu), room-temp, networkable, fidelity question marks for two-qubit gates.

The Competitive Set

The concentrated threat is IBM and Google. They share Rigetti's modality, can outspend it 100-to-1 on R&D, and have explicit roadmaps to fault tolerance. RGTI's defense is architectural specialization (tunable couplers, modular stitching) plus speed, but the moat is narrower than IonQ's modality-based one.

Where RGTI Sits in the Cycle

The Opportunity (TAM)

Quantum computing attacks problems classical machines cannot solve in tractable time, drug & materials discovery, optimization, logistics, finance, cryptography. The market is small today but inflecting: independent forecasters project the quantum-computing provider market growing from roughly $3.5B in 2025 to ~$20B by 2030 (~42% CAGR), with McKinsey estimating up to ~$72B of annual QC revenue by 2035 and BCG projecting $450–850B of cumulative economic value by 2040.

The TAM is identical to the one underwriting the IonQ thesis. What is different is the reasonable share-of-TAM Rigetti can claim. IONQ, with $130M of FY2025 revenue, $470M RPO, blue-chip enterprise customers and the only public trapped-ion brand, is plausibly underwriting 8–12% of quantum-provider dollars by 2030. Rigetti, with one-tenth the revenue base, a less-differentiated modality, and direct exposure to IBM/Google's superconducting roadmap, is more credibly modeled at 1–3% of TAM. That translates to ~$200–600M of 2030 revenue in the bull case, ~$40–120M in the base case, ~$15–40M in the bear case.

Financial Health

FY2024 GAAP revenue was $10.8M (down ~12% YoY on contract timing), with FY2025 guidance framed at $12–15M. Q1 CY2026 came in at ~$4.4M (+193% YoY), beating ~$4.1M consensus and tracking toward the upper half of the FY25 range even before the Ankaa-4 deployment ramp. The GAAP net loss of $201M in FY2024 looks alarming until you separate the components: roughly $140M is non-cash warrant accounting (the legacy SPAC warrants mark to market each quarter), and the adjusted EBITDA loss runs closer to $60–70M annualized. Read the cash burn line, not the headline net loss.

The balance sheet is the cleanest part of the story. $569M cash, equivalents & AFS investments at Q1 CY26 (10-Q dated 2026-03-31) with effectively no traditional debt, against the ~$60–70M operating cash burn rate, implies ~8 years of runway absent a raise. That is well past Ankaa-4 commercialization and the 336-qubit Lyra demonstration, it converts the dilution question from "when forced" to "when opportunistic." The base case still bakes in +20% net dilution from ATM programs across the 2026→2030 window; the bear case +50%.

The cash position has narrowed the gap to the IonQ comp ($569M vs ~$3.1B, still ~5× behind but no longer the dominant downside differentiator it was). The burn ratio (cash / annual operating loss) is now closer to IONQ's: RGTI ~8 years vs IONQ ~9–10 years. The dilution math in section 08 is still material to the per-share fair-value calculation, but it is no longer the existential survival question it was at the $215M cash level.

Cash Runway: Multi-Year, Defensive-Offensive Optionality

Bookings & Backlog

Rigetti does not report Remaining Performance Obligations the way IonQ does. The bookings picture has to be assembled from disclosed contract awards and program participation. The largest single line is the DARPA Quantum Benchmarking Initiative (QBI) Stage A award (up to $1M, April 2025), a 6-month concept-validation grant. RGTI is one of ~15 companies in QBI Stage A; advancement to Stage B was announced November 2025 and remains a near-term catalyst window. Other identifiable government revenue: AFOSR research contracts (~$10–15M cumulative across multiple awards), Innovate UK / NQCC Harwell partnerships (Oxford Instruments collaboration; £3.5M Quantum Missions Pilot with Riverlane), and several smaller DOE national-lab QPU placements.

Commercial revenue, primarily QPU access via AWS Braket, Microsoft Azure Quantum, and direct Rigetti Quantum Cloud Services, runs in the low single-digit-million-dollar range annually. We estimate roughly 70% of FY25E revenue is government-funded, with the balance from commercial cloud access. There is no enterprise customer of the IonQ-AstraZeneca caliber currently disclosed in the RGTI account list. That concentration matters because government revenue, while sticky once awarded, is exposed to appropriations cycles and program-stage advancement decisions, losing QBI Stage B advancement is the single largest single-event risk to the revenue line.

Identifiable Contracts & Partners

Government concentration is sticky but appropriations-exposed. The commercial line, AWS Braket throughput and direct QCS subscriptions, is the variable the bull case needs to inflect. Watch it quarter to quarter; it is reported as a category but rarely broken out in dollar terms.

Valuation & Comps

RGTI trades at roughly 349× trailing (FY24) sales and ~280× FY25E sales. The multiple is eye-watering primarily because the denominator is so small, Rigetti's enterprise value of ~$3.77B is a normal-looking number for a deep-tech name with a credible 2030 roadmap; it is divided by $10.8M of revenue that makes the headline ratio look broken.

The honest reframing is the forward-2030 multiple. At the base-case ~$500M 2030 revenue and a 12× exit EV/Sales, the implied 2030 enterprise value is ~$6.0B, and discounting it back four years at 14% with +20% net dilution lands on ~$11/share, vs the current $14 close. The bull case ($700M at 16×, +10% dilution, 12% WACC) takes that to ~$22; the bear ($250M at 10×, +50% dilution, 18% WACC) to ~$4. That is the EV/Sales-compression chart on the summary page in plain language.

Versus IONQ, the closest direct comp, RGTI's trailing multiple (~349×) is materially richer than IONQ's (~155×) because the revenue base is one-tenth the size. On forward 2030E base, the two compress: RGTI to ~7.5× ($3.77B EV / $500M base 2030 revenue); IONQ to ~15× in our IONQ base scenario.

Valuation Model: Discounted EV/Sales

Pick a ~2030 revenue, an exit EV/Sales multiple, a discount rate and net dilution; the model discounts the implied future enterprise value back four years, adds net cash, and divides by diluted shares. The dilution slider still matters, Rigetti has historically funded operations through ATM programs, but the $569M Q1 CY26 cash position means the base case can be funded with only +20% net dilution across the 2026→2030 window. Use the presets, then move the sliders.

Revenue Ramp & Implied EV ($M)

Sensitivity: Implied Price ($)

Catalysts & Roadmap

Roadmap Milestones

Scenario Targets

This calculator uses the same discounted EV/Sales math at a fixed 14% WACC and 4-year horizon. Move the inputs to see the implied price and a rough scenario-likelihood read. The dilution range still spans 0–80% across the model window, RGTI's ATM history makes dilution path the single biggest swing factor even with the larger $569M cash buffer.

Bull vs Bear

Technicals & Positioning

RGTI is among the most volatile equities in the quantum cohort. The 52-week range, $0.85 to $58.15: is roughly a 68× spread, anchored by a 2024 penny-stock zone and the late-'24/early-'25 quantum-sector rally (Google Willow Dec '24, Microsoft Majorana 1 Feb '25) that carried into a Q3-Q4 2025 momentum peak around $58 in mid-October 2025. At $14 the stock sits well off the high, ~76% below its 52-week high.

Short interest typically runs 18–25% of the float: meaningfully heavier than IONQ, reflecting both the smaller market cap (easier to borrow against) and the structural dilution thesis. That short positioning cuts both ways: it amplifies downside on negative milestones and equity-raise announcements, but it sets up sharp short-squeeze rallies on positive surprises (an Ankaa-4 fidelity beat, a DARPA Phase B win, a sector-wide quantum re-rate).

Risk / Reward Tool

Ask the Thesis AI-assisted checking…

Describe a scenario in natural language; the assistant returns a structured impact analysis against Rigetti's Ankaa roadmap, government-revenue concentration, dilution math, and EV/Sales scenario framework. Powered by Claude via a Cloudflare Worker proxy (Anthropic key held server-side).

Note: The assistant reasons from the dashboard's data snapshot and thesis sections, it does not browse the web or access real-time fundamentals beyond what's in data.js. Treat its responses as scenario-modeling support, not as primary research.

Risks